Pasithea Therapeutics - שולי רווח נקי ממכירות KTTA

Pasithea Therapeutics generates revenue based on the market launch of ketamine-based treatments for CNS therapy. The net margin volume in revenue reflects the impact of these prospects, while 0.00 captures a new level. The success of Pasithea Therapeutics (KTTA) relies on drug safety and R&D budgets, and the development strategy excludes the acquisition of third-party assets, limiting itself to collaborations with research laboratories.
KTTA (Pasithea Therapeutics Corp.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For the Pasithea Therapeutics (KTTA) biotech ecosystem, this indicator determines the monetization efficiency of CNS disorder therapies. The metric is calculated as the ratio of net income to total revenue, measuring the profit share of every dollar earned. By analyzing the net profit margin, an investor assesses the business's ability to control operating expenses. The proprietary clinic network should minimize costs to maintain a stable yield. An increase in this figure confirms the successful scaling of proprietary molecules.